A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Journal of Chemical and Pharmaceutical Research
Ritonavir was originally developed as an inhibitor of HIV protease. It is one of the most complex inhibitors. It is now rarely used for its own antiviral activity, but remains widely used as a booster of other protease inhibitors. cytochrome P450-3A4 (CYP3A4). The drug's molecular structure inhibits CYP3A4, so a low dose can be used to enhance other protease inhibitors. The chromatographic conditions comprise of a column: Zorbax Bonus RP 18, 4.6x100mm, 3.5µ. A mixture of 0.01M Potassiumfatcat:tdxzuxhcqrcvveetrzgp4gsxuq